235 related articles for article (PubMed ID: 33980332)
1. Mast cell activation syndrome: Myths and realities.
Zhang S; Bernstein JA
Allergy Asthma Proc; 2021 May; 42(3):198-204. PubMed ID: 33980332
[No Abstract] [Full Text] [Related]
2. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine.
Valent P; Akin C; Nedoszytko B; Bonadonna P; Hartmann K; Niedoszytko M; Brockow K; Siebenhaar F; Triggiani M; Arock M; Romantowski J; Górska A; Schwartz LB; Metcalfe DD
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261124
[TBL] [Abstract][Full Text] [Related]
3. Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders.
Zaghmout T; Maclachlan L; Bedi N; Gülen T
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):753-761. PubMed ID: 38056692
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals.
González-de-Olano D; Navarro-Navarro P; Muñoz-González JI; Sánchez-Muñoz L; Henriques A; de-Andrés-Martín A; Peralta-Arjonilla D; Mayado A; Jara-Acevedo M; García-Montero AC; Orfao A; Álvarez-Twose I
Allergy; 2024 Mar; 79(3):711-723. PubMed ID: 37818990
[TBL] [Abstract][Full Text] [Related]
5. A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders.
Romantowski J; Górska A; Niedoszytko M; Gulen T; Gruchała-Niedoszytko M; Nedoszytko B; Lange M; Brockow K; Arock M; Akin C; Valent P
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33535634
[TBL] [Abstract][Full Text] [Related]
6. Mast cell activation syndrome: is anaphylaxis part of the phenotype? A systematic review.
Sabato V; Michel M; Blank U; Ebo DG; Vitte J
Curr Opin Allergy Clin Immunol; 2021 Oct; 21(5):426-434. PubMed ID: 34292177
[TBL] [Abstract][Full Text] [Related]
7. How to diagnose mast cell activation syndrome: practical considerations.
Romantowski J; Górska A; Lange M; Nedoszytko B; Gruchała-Niedoszytko M; Niedoszytko M
Pol Arch Intern Med; 2020 Apr; 130(4):317-323. PubMed ID: 32096778
[TBL] [Abstract][Full Text] [Related]
8. A Puzzling Mast Cell Trilogy: Anaphylaxis, MCAS, and Mastocytosis.
Gülen T
Diagnostics (Basel); 2023 Oct; 13(21):. PubMed ID: 37958203
[TBL] [Abstract][Full Text] [Related]
9. Update on idiopathic anaphylaxis.
Calvani M
Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27():52-53. PubMed ID: 35080312
[TBL] [Abstract][Full Text] [Related]
10. Mast cell activation syndromes presenting as anaphylaxis.
Akin C
Immunol Allergy Clin North Am; 2015 May; 35(2):277-85. PubMed ID: 25841551
[TBL] [Abstract][Full Text] [Related]
11. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.
Valent P; Bonadonna P; Hartmann K; Broesby-Olsen S; Brockow K; Butterfield JH; Triggiani M; Lyons JJ; Oude Elberink JNG; Arock M; Metcalfe DD; Akin C
Int Arch Allergy Immunol; 2019; 180(1):44-51. PubMed ID: 31256161
[TBL] [Abstract][Full Text] [Related]
12. Reversible Elevation of Tryptase Over the Individual's Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS?
Valent P; Akin C; Arock M
Curr Allergy Asthma Rep; 2024 Mar; 24(3):133-141. PubMed ID: 38308674
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
Muñoz-González JI; García-Montero AC; Orfao A; Álvarez-Twose I
Ann Allergy Asthma Immunol; 2021 Oct; 127(4):427-434. PubMed ID: 34298172
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic mast cell activation syndrome is more often suspected than diagnosed-A prospective real-life study.
Buttgereit T; Gu S; Carneiro-Leão L; Gutsche A; Maurer M; Siebenhaar F
Allergy; 2022 Sep; 77(9):2794-2802. PubMed ID: 35364617
[TBL] [Abstract][Full Text] [Related]
15. Using the Right Criteria for MCAS.
Gulen T
Curr Allergy Asthma Rep; 2024 Feb; 24(2):39-51. PubMed ID: 38243020
[TBL] [Abstract][Full Text] [Related]
16. Management of Mediator Symptoms, Allergy, and Anaphylaxis in Mastocytosis.
Gulen T
Immunol Allergy Clin North Am; 2023 Nov; 43(4):681-698. PubMed ID: 37758406
[TBL] [Abstract][Full Text] [Related]
17. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes.
Picard M; Giavina-Bianchi P; Mezzano V; Castells M
Clin Ther; 2013 May; 35(5):548-62. PubMed ID: 23642289
[TBL] [Abstract][Full Text] [Related]
18. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.
Valent P; Akin C; Arock M; Brockow K; Butterfield JH; Carter MC; Castells M; Escribano L; Hartmann K; Lieberman P; Nedoszytko B; Orfao A; Schwartz LB; Sotlar K; Sperr WR; Triggiani M; Valenta R; Horny HP; Metcalfe DD
Int Arch Allergy Immunol; 2012; 157(3):215-25. PubMed ID: 22041891
[TBL] [Abstract][Full Text] [Related]
19. Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022.
Valent P; Hartmann K; Bonadonna P; Niedoszytko M; Triggiani M; Arock M; Brockow K
Int Arch Allergy Immunol; 2022; 183(7):693-705. PubMed ID: 35605594
[TBL] [Abstract][Full Text] [Related]
20. Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.
Matito A; Escribese MM; Longo N; Mayorga C; Luengo-Sánchez O; Pérez-Gordo M; Matheu V; Labrador-Horrillo M; Pascal M; Seoane-Reula ME;
J Investig Allergol Clin Immunol; 2021 Dec; 31(6):461-470. PubMed ID: 33541851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
